This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Brandle M, Valentine W, Goodall G, Dumont N, Pang F, Massi Benedetti M.Cost-effectiveness of pioglitazone in type 2 diabetes in Switzerland based on the PROactive study. Diabetologia 50 (Suppl. 1): 428 (plus poster) abstr. 1034, Sep 2007
Ray JA, Valentine WJ, Goodall G, Aagren M, Kotchie RW.Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting. Diabetologia 50 (Suppl. 1): 428 (plus poster) abstr. 1033, Sep 2007
Getsios D, Möller J, McEwan P, Ishak K, Nicholls C, Caro JJ.Treatment with rimonabant for overweight or obese patients with diabetes: health economic estimates for the UK. Diabetologia 50 (Suppl. 1): 345 (plus poster) abstr. 0836, Sep 2007
Duh MS, Gosselin A, Beaulieu N, Arana M, Arondekar B.Comparison of resources utilization and cost in drug-naive type 2 diabetes patients treated with rosiglitazone vs. sulfonylurea monotherapy. Diabetologia 50 (Suppl. 1): 358 (plus poster) abstr. 0867, Sep 2007
Balu S, Lee W, Arondekar B, Horblyuk R, Pashos C.Economic analysis of thiazolidinedione add-on therapy relative to insulin add-on therapy in individuals treated with sulfonylureas: a third party payer's perspective. Diabetologia 50 (Suppl. 1): 358 (plus poster) abstr. 0868, Sep 2007
Arondekar B, Balu S, Lee W, Horblyuk R, Pashos C.Economic impact of add-on therapy with thiazolidinedione versus insulin to metformin monotherapy. Diabetologia 50 (Suppl. 1): 358-359 (plus poster) abstr. 0869, Sep 2007
Rights and permissions
About this article
Cite this article
News from EASD. Pharmacoecon. Outcomes News 538, 5–6 (2007). https://doi.org/10.2165/00151234-200705380-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705380-00013